By Mill Chart
Last update: Jun 9, 2025
ADMA BIOLOGICS INC (NASDAQ:ADMA) was identified by our screener as a strong growth stock with a favorable technical setup. The company combines solid fundamental growth metrics with a promising chart pattern, making it a candidate worth further examination.
ADMA Biologics operates in the biotechnology sector, specializing in plasma-derived therapies. The company’s fundamentals reflect strong growth potential:
The company’s financial health is also sound, with a high solvency score and manageable debt levels.
The stock’s technical analysis suggests a consolidation phase with potential for an upward breakout:
ADMA’s relative strength is notable, outperforming 95% of stocks over the past year and 93% of biotechnology peers.
Growth stocks with strong technical setups often present favorable risk-reward opportunities. ADMA’s fundamentals suggest sustained expansion, while its chart indicates a potential breakout after recent consolidation. Investors looking for growth exposure with a defined technical entry may find this setup appealing.
For more details, review the full fundamental report and technical analysis.
Our Strong Growth Stocks with Good Technical Setup Ratings screener lists additional candidates updated daily.
This is not investment advice. The observations here are based on current data, but market conditions can change. Always conduct your own research before making investment decisions.
20.61
+0.67 (+3.36%)
Find more stocks in the Stock Screener
ADMA Biologics (NASDAQ:ADMA) shows strong growth fundamentals and a technical breakout setup, making it a stock to watch in the biotech sector.
ADMA Biologics (NASDAQ:ADMA) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has outperformed peers and may present a breakout opportunity.
ADMA Biologics (NASDAQ:ADMA) shows strong growth, reasonable valuation, and solid financial health, making it an attractive candidate for investors seeking affordable growth stocks in the biotech sector.